Evgen Pharma PLC Notice of Investor Symposium (3379A)
September 11 2018 - 2:01AM
UK Regulatory
TIDMEVG
RNS Number : 3379A
Evgen Pharma PLC
11 September 2018
For immediate release 11 September 2018
Evgen Pharma plc
("Evgen" or "the Company")
Notice of Investor Symposium
The clinical significance of SFX-01
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, is to hold an Investor Symposium for investors and
analysts on the morning of Tuesday 18 September 2018.
The Investor Symposium, titled "The clinical significance of
SFX-01", will be an opportunity to engage with the Company and
independent experts to help frame the significance of the two Phase
II clinical read-outs of SFX-01 expected around the end of the
year.
The morning will feature a short introduction by Evgen's CEO,
Stephen Franklin, followed by a series of presentations and a
Q&A session. The presentations will include:
-- Vadim Alexandre - Managing Director, Northland Capital Partners
The biotech investment market and Evgen Pharma plc
-- Prof Albena Dinkova-Kostova - University of Dundee
The science behind sulforaphane
-- Dr Sasha Howell - The Christie Hospital, Manchester
The STEM trial in breast cancer
-- Sally Ross - Clinical Development Officer, Evgen
The SAS trial in haemorrhagic stroke and the preclinical
pipeline
The event will be held at the offices of Buchanan, 107
Cheapside, London EC2V 6DN and will begin at 9.15am. The
presentations will be available on the Company website on the day.
No new material trading information will be disclosed.
If you wish to attend the event, please register your interest
with Buchanan on 020 7466 5000 or email tillya@buchanan.uk.com
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Tilly Abraham +44 (0) 20 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Tom Price, Gerry Beaney
(Corporate Finance)
Rob Rees (Corporate Broking) +44 (0) 20 3861 6625
WG Partners LLP
Nigel Barnes, Claes Spång +44 (0) 20 3705 9330
Notes for editors:
About Evgen Pharma plc
Evgen is a clinical stage drug development company whose lead
programmes are in breast cancer and subarachnoid haemorrhage, a
type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office at the Liverpool Science Park, Liverpool. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLFFIIADIILIT
(END) Dow Jones Newswires
September 11, 2018 02:01 ET (06:01 GMT)
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From Apr 2024 to May 2024
Evgen Pharma (LSE:EVG)
Historical Stock Chart
From May 2023 to May 2024